Is Lixte Biotechnology Stock a Good Investment?
Lixte Biotechnology Investment Advice | LIXTW |
- Examine Lixte Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lixte Biotechnology's leadership team and their track record. Good management can help Lixte Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lixte Biotechnology's business and its evolving consumer preferences.
- Compare Lixte Biotechnology's performance and market position to its competitors. Analyze how Lixte Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if Lixte Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lixte Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lixte Biotechnology Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lixte Biotechnology Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Lixte Biotechnology Stock
Researching Lixte Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Lixte Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lixte Biotechnology's research are outlined below:
| Lixte Biotechnology is way too risky over 90 days horizon | |
| Lixte Biotechnology has some characteristics of a very speculative penny stock | |
| Lixte Biotechnology appears to be risky and price may revert if volatility continues | |
| Lixte Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (3.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lixte Biotechnology Holdings has accumulated about 1.08 M in cash with (3.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Lixte Biotechnology terminates sales agreement with Wallachbeth Capital -March 11, 2025 at 1035 am EDT - Marketscreener.com |
Lixte Biotechnology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.49 M.Market Cap |
|
Lixte Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.13) | (3.29) | |
| Return On Capital Employed | (4.32) | (4.53) | |
| Return On Assets | (3.13) | (3.29) | |
| Return On Equity | (4.33) | (4.55) |
Determining Lixte Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if Lixte Biotechnology is a good buy. For example, gross profit margin measures Lixte Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lixte Biotechnology's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Lixte Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lixte Biotechnology Holdings. Check Lixte Biotechnology's Beneish M Score to see the likelihood of Lixte Biotechnology's management manipulating its earnings.
Evaluate Lixte Biotechnology's management efficiency
Lixte Biotechnology has return on total asset (ROA) of (0.8188) % which means that it has lost $0.8188 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4873) %, meaning that it generated substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -3.29 in 2025. Return On Capital Employed is likely to drop to -4.53 in 2025. At this time, Lixte Biotechnology's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 100 K in 2025, whereas Non Current Assets Total are likely to drop 0.00 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.37 | 0.35 | |
| Tangible Book Value Per Share | 0.37 | 0.35 | |
| Enterprise Value Over EBITDA | (0.99) | (1.04) | |
| Price Book Value Ratio | 5.52 | 5.80 | |
| Enterprise Value Multiple | (0.99) | (1.04) | |
| Price Fair Value | 5.52 | 5.80 | |
| Enterprise Value | 4.1 M | 3.9 M |
Understanding the operational decisions made by Lixte Biotechnology management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.188 |
Basic technical analysis of Lixte Stock
As of the 28th of March, Lixte Biotechnology secures the Risk Adjusted Performance of 0.1141, mean deviation of 10.7, and Downside Deviation of 22.32. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lixte Biotechnology, as well as the relationship between them. Please verify Lixte Biotechnology standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Lixte Biotechnology Holdings is priced some-what accurately, providing market reflects its recent price of 0.034 per share. As Lixte Biotechnology appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.Lixte Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lixte Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lixte Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lixte Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Forman Eric over six months ago Acquisition by Forman Eric of 2500 shares of Lixte Biotechnology at 0.5599 subject to Rule 16b-3 | ||
Robert Weingarten over six months ago Acquisition by Robert Weingarten of 200000 shares of Lixte Biotechnology subject to Rule 16b-3 | ||
Bernards Rene over six months ago Acquisition by Bernards Rene of 10000 shares of Lixte Biotechnology at 0.61 subject to Rule 16b-3 | ||
Bernards Rene over six months ago Acquisition by Bernards Rene of 5527 shares of Lixte Biotechnology at 2.51 subject to Rule 16b-3 |
Understand Lixte Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lixte Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1141 | |||
| Market Risk Adjusted Performance | 2.33 | |||
| Mean Deviation | 10.7 | |||
| Semi Deviation | 11.25 | |||
| Downside Deviation | 22.32 | |||
| Coefficient Of Variation | 797.22 | |||
| Standard Deviation | 20.11 | |||
| Variance | 404.44 | |||
| Information Ratio | 0.1262 | |||
| Jensen Alpha | 2.54 | |||
| Total Risk Alpha | 3.14 | |||
| Sortino Ratio | 0.1137 | |||
| Treynor Ratio | 2.32 | |||
| Maximum Drawdown | 123.64 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 33.33 | |||
| Downside Variance | 498.25 | |||
| Semi Variance | 126.61 | |||
| Expected Short fall | (34.64) | |||
| Skewness | 1.59 | |||
| Kurtosis | 8.35 |
| Risk Adjusted Performance | 0.1141 | |||
| Market Risk Adjusted Performance | 2.33 | |||
| Mean Deviation | 10.7 | |||
| Semi Deviation | 11.25 | |||
| Downside Deviation | 22.32 | |||
| Coefficient Of Variation | 797.22 | |||
| Standard Deviation | 20.11 | |||
| Variance | 404.44 | |||
| Information Ratio | 0.1262 | |||
| Jensen Alpha | 2.54 | |||
| Total Risk Alpha | 3.14 | |||
| Sortino Ratio | 0.1137 | |||
| Treynor Ratio | 2.32 | |||
| Maximum Drawdown | 123.64 | |||
| Value At Risk | (25.00) | |||
| Potential Upside | 33.33 | |||
| Downside Variance | 498.25 | |||
| Semi Variance | 126.61 | |||
| Expected Short fall | (34.64) | |||
| Skewness | 1.59 | |||
| Kurtosis | 8.35 |
Consider Lixte Biotechnology's intraday indicators
Lixte Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lixte Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.034 | |||
| Day Typical Price | 0.034 | |||
| Price Action Indicator | (0.0005) | |||
| Period Momentum Indicator | (0) | |||
| Relative Strength Index | 47.5 |
Lixte Stock media impact
Far too much social signal, news, headlines, and media speculation about Lixte Biotechnology that are available to investors today. That information is available publicly through Lixte media outlets and privately through word of mouth or via Lixte internal channels. However, regardless of the origin, that massive amount of Lixte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lixte Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lixte Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lixte Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lixte Biotechnology alpha.
Lixte Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lixte Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lixte Biotechnology Corporate Management
| John Kovach | Chairman, Founder | Profile | |
| Esq JD | Consultant | Profile | |
| Johannes MD | Chief Officer | Profile | |
| James MD | Chief Officer | Profile | |
| Robert Weingarten | VP CFO | Profile | |
| Eric JD | Chief Officer | Profile |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.